Surveillance of adverse reactions due to ciprofloxacin in Japan.
Matsuno
K
K
PMS Control, Bayer Yakuhin Ltd, Osaka, Japan.
Kunihiro
E
E
Yamatoya
O
O
Miyata
K
K
Hasegawa
H
H
Fujita
H
H
Yamauchi
K
K
Hirakawa
Y
Y
D000293:Adolescent; D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000009:adverse effects*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D002648:Child; D002939:Ciprofloxacin / Q000009:adverse effects*; D004342:Drug Hypersensitivity / Q000453:epidemiology; D004347:Drug Interactions; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced / Q000453:epidemiology; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D011358:Product Surveillance, Postmarketing
D000890:Anti-Infective Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D002939:Ciprofloxacin